Autres langues Lipigon Pharmaceuticals AB

Actions

LPGO

SE0015382072

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,26 ^SEK	-1,14%		-16,13%	-39,68%

20/06	Lipigon Pharmaceuticals AB (publ) annonce que la protéine ANGPTL4 pourrait réduire le risque de maladie cardiovasculaire et de diabète	CI
28/05	Lipigon Pharmaceuticals AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lipigon Pharmaceuticals AB Announces ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes	20/06
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	28/05
Lipigon Pharmaceuticals AB and Leaderna Therapeutics Collaboration on Lipisense® Shows Good Progress	15/05
Lipigon Pharmaceuticals AB Collaborates with University of Washington on Lung Damage Project	14/05
Lipigon Collaborates with University of Washington on Lung Damage Project	14/05
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02
Lipigon Pharmaceuticals’ Lipisense Gets Swedish Regulators' Nod for Mid-stage Study	07/02
The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense	07/02
Lipigon Pharmaceuticals AB Announces Lipisense Progressing to Phase II Trials	12/12
Lipigon Pharmaceuticals AB Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ®	23/11
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23/11
Lipigon Applies for Clinical Trial Phase II for Lipisense	13/11
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/08/23
Lipigon Pharmaceuticals AB Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial	12/07/23
Lipigon Pharmaceuticals Surges 40% on Lipisense Development, Licensing Deal in China	27/06/23
Lipigon Announces Development and License Agreement with Leaderna Therapeutics Ltd	27/06/23
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023	25/05/23
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	28/02/23
Lipigon Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23
Lipigon Announces Further Positive Data from Phase I Trial of Lipisense	19/01/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lipigon Pharmaceuticals AB

Actions

LPGO

SE0015382072

Autres langues

Filtres